Altrecht   Report issue

Academic/Hospital Phase 3
Founded: Den Dolder Netherlands (1999)

Organization Overview

First Clinical Trial
2016
NCT03043820
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Altrecht | Altrecht GGZ

Active Ingredients

Drugs in Phase 3 Trials (1)

raloxifene (evista) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 3)

Mental Disorders (Phase 3)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1